Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody

Allison F. O'Neill, Jason L J Dearling, Yuchuan Wang, Tanya Tupper, Yanping Sun, Jon C. Aster, Monica L. Calicchio, Antonio R. Perez-Atayde, Alan B. Packard, Andrew L. Kung

Research output: Contribution to journalArticle

Abstract

Purpose: Ewing sarcoma is a tumor of the bone and soft tissue characterized by diffuse cell membrane expression of CD99 (MIC2). Single-site, surgically resectable disease is associated with an excellent 5-year event-free survival; conversely, patients with distant metastases have a poor prognosis. Noninvasive imaging is the standard approach to identifying sites of metastatic disease. We sought to develop a CD99-targeted imaging agent for staging Ewing sarcoma and other CD99-expressing tumors. Experimental Design: We identified a CD99 antibody with highly specific binding in vitro and labeled this antibody with 64Cu. Mice with either subcutaneous Ewing sarcoma xenograft tumors or micrometastases were imaged with the 64Cu-labeled anti-CD99 antibody and these results were compared with conventional MRI and 2[18F]fluoro-2-deoxy- D-glucose-positron emission tomography (FDG-PET) imaging. Results: 64Cu-labeled anti-CD99 antibody demonstrated high avidity for the CD99-positive subcutaneous tumors, with a high tumor-to-background ratio, greater than that demonstrated with FDG-PET. Micrometastases, measuring 1 to 2 mm on MRI, were not detected with FDG-PET but were readily visualized with the 64Cu-labeled anti-CD99 antibody. Probe biodistribution studies demonstrated high specificity of the probe for CD99-positive tumors. Conclusions: 64Cu-labeled anti-CD99 antibody can detect subcutaneous Ewing sarcoma tumors and metastatic sites with high sensitivity, outperforming FDG-PET in preclinical studies. This targeted radiotracer may have important implications for the diagnosis, surveillance, and treatment of Ewing sarcoma. Similarly, it may impact the management of other CD99 positive tumors.

Original languageEnglish (US)
Pages (from-to)678-687
Number of pages10
JournalClinical Cancer Research
Volume20
Issue number3
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Anti-Idiotypic Antibodies
Positron-Emission Tomography
Deoxyglucose
Neoplasms
Neoplasm Micrometastasis
Antibodies
Fluorodeoxyglucose F18
Heterografts
Disease-Free Survival
Research Design
Cell Membrane
Neoplasm Metastasis
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

O'Neill, A. F., Dearling, J. L. J., Wang, Y., Tupper, T., Sun, Y., Aster, J. C., ... Kung, A. L. (2014). Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. Clinical Cancer Research, 20(3), 678-687. https://doi.org/10.1158/1078-0432.CCR-13-1660

Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. / O'Neill, Allison F.; Dearling, Jason L J; Wang, Yuchuan; Tupper, Tanya; Sun, Yanping; Aster, Jon C.; Calicchio, Monica L.; Perez-Atayde, Antonio R.; Packard, Alan B.; Kung, Andrew L.

In: Clinical Cancer Research, Vol. 20, No. 3, 2014, p. 678-687.

Research output: Contribution to journalArticle

O'Neill, AF, Dearling, JLJ, Wang, Y, Tupper, T, Sun, Y, Aster, JC, Calicchio, ML, Perez-Atayde, AR, Packard, AB & Kung, AL 2014, 'Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody', Clinical Cancer Research, vol. 20, no. 3, pp. 678-687. https://doi.org/10.1158/1078-0432.CCR-13-1660
O'Neill, Allison F. ; Dearling, Jason L J ; Wang, Yuchuan ; Tupper, Tanya ; Sun, Yanping ; Aster, Jon C. ; Calicchio, Monica L. ; Perez-Atayde, Antonio R. ; Packard, Alan B. ; Kung, Andrew L. / Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 3. pp. 678-687.
@article{a58c4b49cad94078b27428775d6176c1,
title = "Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody",
abstract = "Purpose: Ewing sarcoma is a tumor of the bone and soft tissue characterized by diffuse cell membrane expression of CD99 (MIC2). Single-site, surgically resectable disease is associated with an excellent 5-year event-free survival; conversely, patients with distant metastases have a poor prognosis. Noninvasive imaging is the standard approach to identifying sites of metastatic disease. We sought to develop a CD99-targeted imaging agent for staging Ewing sarcoma and other CD99-expressing tumors. Experimental Design: We identified a CD99 antibody with highly specific binding in vitro and labeled this antibody with 64Cu. Mice with either subcutaneous Ewing sarcoma xenograft tumors or micrometastases were imaged with the 64Cu-labeled anti-CD99 antibody and these results were compared with conventional MRI and 2[18F]fluoro-2-deoxy- D-glucose-positron emission tomography (FDG-PET) imaging. Results: 64Cu-labeled anti-CD99 antibody demonstrated high avidity for the CD99-positive subcutaneous tumors, with a high tumor-to-background ratio, greater than that demonstrated with FDG-PET. Micrometastases, measuring 1 to 2 mm on MRI, were not detected with FDG-PET but were readily visualized with the 64Cu-labeled anti-CD99 antibody. Probe biodistribution studies demonstrated high specificity of the probe for CD99-positive tumors. Conclusions: 64Cu-labeled anti-CD99 antibody can detect subcutaneous Ewing sarcoma tumors and metastatic sites with high sensitivity, outperforming FDG-PET in preclinical studies. This targeted radiotracer may have important implications for the diagnosis, surveillance, and treatment of Ewing sarcoma. Similarly, it may impact the management of other CD99 positive tumors.",
author = "O'Neill, {Allison F.} and Dearling, {Jason L J} and Yuchuan Wang and Tanya Tupper and Yanping Sun and Aster, {Jon C.} and Calicchio, {Monica L.} and Perez-Atayde, {Antonio R.} and Packard, {Alan B.} and Kung, {Andrew L.}",
year = "2014",
doi = "10.1158/1078-0432.CCR-13-1660",
language = "English (US)",
volume = "20",
pages = "678--687",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Targeted imaging of ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody

AU - O'Neill, Allison F.

AU - Dearling, Jason L J

AU - Wang, Yuchuan

AU - Tupper, Tanya

AU - Sun, Yanping

AU - Aster, Jon C.

AU - Calicchio, Monica L.

AU - Perez-Atayde, Antonio R.

AU - Packard, Alan B.

AU - Kung, Andrew L.

PY - 2014

Y1 - 2014

N2 - Purpose: Ewing sarcoma is a tumor of the bone and soft tissue characterized by diffuse cell membrane expression of CD99 (MIC2). Single-site, surgically resectable disease is associated with an excellent 5-year event-free survival; conversely, patients with distant metastases have a poor prognosis. Noninvasive imaging is the standard approach to identifying sites of metastatic disease. We sought to develop a CD99-targeted imaging agent for staging Ewing sarcoma and other CD99-expressing tumors. Experimental Design: We identified a CD99 antibody with highly specific binding in vitro and labeled this antibody with 64Cu. Mice with either subcutaneous Ewing sarcoma xenograft tumors or micrometastases were imaged with the 64Cu-labeled anti-CD99 antibody and these results were compared with conventional MRI and 2[18F]fluoro-2-deoxy- D-glucose-positron emission tomography (FDG-PET) imaging. Results: 64Cu-labeled anti-CD99 antibody demonstrated high avidity for the CD99-positive subcutaneous tumors, with a high tumor-to-background ratio, greater than that demonstrated with FDG-PET. Micrometastases, measuring 1 to 2 mm on MRI, were not detected with FDG-PET but were readily visualized with the 64Cu-labeled anti-CD99 antibody. Probe biodistribution studies demonstrated high specificity of the probe for CD99-positive tumors. Conclusions: 64Cu-labeled anti-CD99 antibody can detect subcutaneous Ewing sarcoma tumors and metastatic sites with high sensitivity, outperforming FDG-PET in preclinical studies. This targeted radiotracer may have important implications for the diagnosis, surveillance, and treatment of Ewing sarcoma. Similarly, it may impact the management of other CD99 positive tumors.

AB - Purpose: Ewing sarcoma is a tumor of the bone and soft tissue characterized by diffuse cell membrane expression of CD99 (MIC2). Single-site, surgically resectable disease is associated with an excellent 5-year event-free survival; conversely, patients with distant metastases have a poor prognosis. Noninvasive imaging is the standard approach to identifying sites of metastatic disease. We sought to develop a CD99-targeted imaging agent for staging Ewing sarcoma and other CD99-expressing tumors. Experimental Design: We identified a CD99 antibody with highly specific binding in vitro and labeled this antibody with 64Cu. Mice with either subcutaneous Ewing sarcoma xenograft tumors or micrometastases were imaged with the 64Cu-labeled anti-CD99 antibody and these results were compared with conventional MRI and 2[18F]fluoro-2-deoxy- D-glucose-positron emission tomography (FDG-PET) imaging. Results: 64Cu-labeled anti-CD99 antibody demonstrated high avidity for the CD99-positive subcutaneous tumors, with a high tumor-to-background ratio, greater than that demonstrated with FDG-PET. Micrometastases, measuring 1 to 2 mm on MRI, were not detected with FDG-PET but were readily visualized with the 64Cu-labeled anti-CD99 antibody. Probe biodistribution studies demonstrated high specificity of the probe for CD99-positive tumors. Conclusions: 64Cu-labeled anti-CD99 antibody can detect subcutaneous Ewing sarcoma tumors and metastatic sites with high sensitivity, outperforming FDG-PET in preclinical studies. This targeted radiotracer may have important implications for the diagnosis, surveillance, and treatment of Ewing sarcoma. Similarly, it may impact the management of other CD99 positive tumors.

UR - http://www.scopus.com/inward/record.url?scp=84893509699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893509699&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-1660

DO - 10.1158/1078-0432.CCR-13-1660

M3 - Article

C2 - 24218512

AN - SCOPUS:84893509699

VL - 20

SP - 678

EP - 687

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -